It was clearly demonstrated that treating moderate COVID-19 cases with IFN-α2b could accelerate viral clearance while maintaining adequate levels of circulating pro-inflammatory cytokines such as IL-6 and CRP (C-reactive protein) to strengthen the patients’ immunity against the disease [72]. The gene discussed is IL6; the disease is COVID-19.